Kite, a Gilead Company, has announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a ...

Here are the nominees for the Marion Star Football Player of Week 1 Poll that runs through early Tuesday morning.

The Handmaid's Tale is full of ostensibly harmless-sounding catchphrases whose entire meaning only reveals itself when read ...

It was a new season, but Jonathan Alder’s football squad made a big statement. The Pioneers started the year on the road at ...

Mt. Gilead State Park may not boast the expansive acreage of its larger cousins in the Ohio state park system, but what this woodland gem lacks in size, it delivers tenfold in tranquility, ...

Marion Harding kicked off the C.J. Westler Era with a victory for its new head coach. The Presidents went to Mount Vernon and ...

We write as members of the international medical community to call upon the Israeli Medical Association (IMA) to uphold its commitment to ethical principles by supporting independent international ...

At Martha’s Vineyard, Touch Talks Wellness and BlackDoctor.org joined forces to host an urgent and deeply personal conversation on cancer disparities in the Black community. Powered by partnerships ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

The major indexes close the day with losses on Thursday after wavering earlier in the session. Palantir stock adds suspense.